Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thean who wrote (69)	4/4/1997 2:35:00 PM
From: Henry Niman	of 965

I believe that CenTNF is an antibody directed against Tumor Necrosis Factor and I think it is the same as cA2. -- Morgan Stanley analyst Eric Hecht said he reiterated his strong buy rating on Centocor Inc due to his expectations for its anti-inflamatory drug CenTNF. -- He said the drug for treating Crohn's disease, a severe inflamatory bowel condition, and rheumatoid arthritis, could be a "big opportunity" for Centocor, with peak annual sales reaching $500 million. -- He said the peak sales could be reached in four to five years from the product's expected launch in 1998. -- He raised his price target on the stock to $51 from $40. The stock rose five to 34. REUTER Rtr 13:46 12-03-96 Henry

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next